Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.74 |
| ▸ | KDM1A | O60341 | 2/20 | 0.72 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.54 |
| ▸ | CCR9 | P51686 | 3/20 | 0.52 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.52 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.52 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.52 |
| ▸ | UQCRB | P14927 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649661 | 0.88 | METAP2 (0.57) | METAP2KDM1AHSD17B2CCR9SLC10A2 | |
| SCHEMBL2532893 | 0.87 | ALDH1A1 (0.65) | METAP2KDM1AHSD17B2CCR9SLC10A6 | |
| SCHEMBL19083016 | 0.85 | METAP2 (1.00) | METAP2KDM1ACCR9SLC10A2SLC10A1 | |
| SCHEMBL1093574 | 0.85 | CCR9 (0.70) | METAP2HSD17B2CCR9CCR2 | |
| SCHEMBL7213164 | 0.84 | SLC10A6 (0.71) | METAP2KDM1APTPN5HSD17B2SLC10A2 | |
| SCHEMBL5925257 | 0.83 | METAP2 (1.00) | METAP2KDM1ACCR9SLC10A2SLC10A1 | |
| SCHEMBL343780 | 0.83 | CCR9 (0.78) | KDM1ACCR9CCR2 | |
| SCHEMBL1104720 | 0.81 | PTPN5 (0.58) | METAP2KDM1APTPN5HSD17B2UQCRB | |
| SCHEMBL16574547 | 0.80 | CCR9 (0.61) | METAP2KDM1ACCR9UQCRB | |
| SCHEMBL3994870 | 0.80 | HSD17B2 (0.54) | METAP2KDM1AHSD17B2CCR9UQCRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | claimed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | METAP2 1707/4885KDM1A 2113/4885PTPN5 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.